Akriti Jain

759 total citations
88 papers, 409 citations indexed

About

Akriti Jain is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Akriti Jain has authored 88 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 26 papers in Oncology and 25 papers in Genetics. Recurrent topics in Akriti Jain's work include Acute Myeloid Leukemia Research (32 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Akriti Jain is often cited by papers focused on Acute Myeloid Leukemia Research (32 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Akriti Jain collaborates with scholars based in United States, India and Pakistan. Akriti Jain's co-authors include Kendra Sweet, Sarfraz Ahmad, Rami S. Komrokji, Ishtiaq Hussain, Jeffrey E. Lancet, Waqas Ullah, Mamoon Ur Rashid, Somedeb Ball, David A. Sallman and Eric Padron and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Akriti Jain

73 papers receiving 406 citations

Peers

Akriti Jain

ONCOL

HEMAT

GENET

PRM

Geoffroy Venton France

Masatoshi Sakurai Japan

Giammarco Surico Italy

Geetha Narayanan India

Sophie Rigaudeau France

Bachar Samra United States

Uta Brunnberg Germany

Seçkin Çağırgan Türkiye

Anand Pathak United States

Amine Belhabri France

Geoffroy Venton France

Akriti Jain

116 ×0.8

ONCOL

191 ×1.4

HEMAT

147 ×1.2

101 ×1.3

GENET

52 ×0.9

PRM

Citations per year, relative to Akriti Jain Akriti Jain (= 1×) peers Geoffroy Venton

Countries citing papers authored by Akriti Jain

Since Specialization

Citations

This map shows the geographic impact of Akriti Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akriti Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akriti Jain more than expected).

Fields of papers citing papers by Akriti Jain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akriti Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akriti Jain. The network helps show where Akriti Jain may publish in the future.

Co-authorship network of co-authors of Akriti Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Akriti Jain. A scholar is included among the top collaborators of Akriti Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akriti Jain. Akriti Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Meera, Emily C. Zabor, Hadil Zureigat, et al.. (2025). Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center. Leukemia & lymphoma. 66(8). 1509–1514.

Samaras, Christy, Akriti Jain, Jason Valent, et al.. (2025). Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?. Blood. 146(Supplement 1). 2248–2248.

Aguirre, Luis E., Somedeb Ball, Akriti Jain, et al.. (2025). Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clinical Lymphoma Myeloma & Leukemia. 25(9). 661–671.

Jain, Akriti & Jörge E. Cortes. (2025). Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action. Expert Opinion on Pharmacotherapy. 26(6). 677–684.

Jain, Akriti, Somedeb Ball, Onyee Chan, et al.. (2024). Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Annals of Hematology. 103(6). 1941–1945. 5 indexed citations

Calabrese, Cassandra, et al.. (2024). Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review. Leukemia Research. 146. 107584–107584. 3 indexed citations

Jain, Akriti, Chen Wang, Somedeb Ball, et al.. (2024). Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Annals of Hematology. 104(1). 307–315. 2 indexed citations

Aguirre, Luis E., Akriti Jain, Somedeb Ball, et al.. (2024). Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clinical Lymphoma Myeloma & Leukemia. 24(7). 459–467. 2 indexed citations

Jain, Akriti, Madelyn Burkart, Xiaoyue Ma, et al.. (2024). Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2867–2867.

10.

Lemoli, Roberto M., Pau Montesinos, & Akriti Jain. (2023). Real-world experience with CPX-351 in high-risk acute myeloid leukemia. Critical Reviews in Oncology/Hematology. 185. 103984–103984. 9 indexed citations

11.

Giuliano, Anna R., Barbara J. Kuter, Shari Pilon‐Thomas, et al.. (2023). Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients. Cancer Communications. 43(7). 749–764. 6 indexed citations

12.

Zhang, Ling, Akriti Jain, Lubomir Sokol, et al.. (2023). Delineation of clinical course, outcomes, and prognostic factors in patients with T‐cell prolymphocytic leukemia. American Journal of Hematology. 98(6). 913–921. 4 indexed citations

13.

Aguirre, Luis E., Akriti Jain, Somedeb Ball, et al.. (2021). Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Blood. 138(Supplement 1). 1494–1494. 7 indexed citations

14.

Jain, Akriti, et al.. (2020). Not All Herbals are Benign: A Case of Hydroxycut-induced Acute Liver Injury. Cureus. 12(2). e6870–e6870. 8 indexed citations

15.

Jain, Akriti, et al.. (2020). An Unusual Case of Alveolar Rhabdomyosarcoma of the Neck in an Adult Patient. Cureus. 12(1). e6745–e6745. 1 indexed citations

16.

Wang, Ren‐Ching, Luwei Tao, Akriti Jain, et al.. (2019). Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma. Cureus. 11(4). e4401–e4401. 7 indexed citations

17.

Jain, Akriti, et al.. (2019). Plasma cell leukemia - one in a million: A case report. World Journal of Clinical Oncology. 10(3). 161–165.

18.

Rashid, Mamoon Ur, et al.. (2019). Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer. Critical Reviews™ in Oncogenesis. 24(2). 199–212. 83 indexed citations

19.

Jain, Akriti, et al.. (2019). Sudden Loss of Vision: An Insight into Rivaroxaban. Cureus. 11(4). e4542–e4542. 1 indexed citations

20.

Jain, Akriti, et al.. (2019). Pyoderma Gangrenosum in the Absence of Any Underlying Predisposing Condition: A Diagnostic Dilemma. Cureus. 11(3). e4213–e4213. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact